- Home
- ESBA vs DNLI Comparison
ESBA vs DNLI Comparison
Compare ESBA & DNLI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ESBA
- DNLI
- Stock Information
- Founded
- ESBA N/A
- DNLI 2013
- Country
- ESBA United States
- DNLI United States
- Employees
- ESBA N/A
- DNLI N/A
- Industry
- ESBA
- DNLI Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- ESBA
- DNLI Health Care
- Exchange
- ESBA NYSE
- DNLI Nasdaq
- Market Cap
- ESBA 2.2B
- DNLI 1.8B
- IPO Year
- ESBA 2013
- DNLI 2017
- Fundamental
- Price
- ESBA N/A
- DNLI $12.74
- Analyst Decision
- ESBA
- DNLI Strong Buy
- Analyst Count
- ESBA 0
- DNLI 16
- Target Price
- ESBA N/A
- DNLI $37.57
- AVG Volume (30 Days)
- ESBA 5.8K
- DNLI 1.7M
- Earning Date
- ESBA 01-01-0001
- DNLI 05-06-2025
- Dividend Yield
- ESBA 2.02%
- DNLI N/A
- EPS Growth
- ESBA N/A
- DNLI N/A
- EPS
- ESBA 0.28
- DNLI N/A
- Revenue
- ESBA $763,152,000.00
- DNLI N/A
- Revenue This Year
- ESBA N/A
- DNLI N/A
- Revenue Next Year
- ESBA N/A
- DNLI $372.05
- P/E Ratio
- ESBA $24.91
- DNLI N/A
- Revenue Growth
- ESBA 3.19
- DNLI N/A
- 52 Week Low
- ESBA $6.39
- DNLI $10.57
- 52 Week High
- ESBA $11.50
- DNLI $33.33
- Technical
- Relative Strength Index (RSI)
- ESBA 35.45
- DNLI 42.15
- Support Level
- ESBA $6.70
- DNLI $12.37
- Resistance Level
- ESBA $7.07
- DNLI $13.63
- Average True Range (ATR)
- ESBA 0.27
- DNLI 1.24
- MACD
- ESBA 0.03
- DNLI 0.23
- Stochastic Oscillator
- ESBA 40.14
- DNLI 50.94
About ESBA EMPIRE STATE REALTY OP LIM PARTNER
Empire State Realty OP LP is an NYC-focused real estate investment trust (REIT) that owns and operates a portfolio of well-leased, top-of-tier, modernized, amenitized, and well-located office, retail, and multifamily assets, conducts all of its business and owns substantially all of its assets. The firm operates in two segments, Real Estate and Observatory. Through the Real Estate segment, it offers services related to the ownership, management, operation, acquisition, repositioning and disposition of its real estate assets. Under the Observatory segment, it operates the two observatories of the Empire State Building. The company generates maximum revenue from the Real Estate segment.
About DNLI Denali Therapeutics Inc.
Denali Therapeutics Inc is a biotechnology company that is engaged in developing and discovering therapeutics to defeat neurodegeneration disease. The company's development programs include the LRRK2 Inhibitor Program, which develops brain penetrant small molecule LRRK2 inhibitor product candidates for Parkinson's disease. Its key products include DNL201, DNL151, DNL747, ATV (Antibody Transport Vehicle), ETV (Enzyme Transport Vehicle), and others.